Kansas City Chapter
Andrea Harper, Chapter Engagement Manager - Midwest
We are actively recruiting leadership in the Kansas City chapter! For more information, please reach out to Andrea Harper at AHarper@FightingBlindness.org.
The Strength of the Foundation is Through Our Communities
The Foundation Fighting Blindness Chapter network brings people together across the country to join in fighting blinding retinal diseases. Our family of volunteers and leaders stand up for those impacted by blinding diseases. From day one, they share the latest research and advancements, and provide access to local resources to guide individuals through their personal journey. And together, they celebrate the Foundation’s mission.
We are winning thanks to the dedication of our Chapters focusing on three key areas: education, resources, and revenue. Through informative sessions, Foundation staff, community, and national experts provide research information, low vision resources, and outreach to our local retinal specialists and eye care professionals. To continue accelerating our mission, each community is invited to be a stakeholder by participating in our fundraising events.
The Foundation Fighting Blindness Chapter Vision
Our vision is to bring a community together to end blinding diseases.
Kansas City Chapter Leadership
|Terry Super||Chapter President|
|Teri Wichman||Education Chair|
Chapter Engagement Manager - Midwest
This event will be featuring updates from the Foundation Fighting Blindness Kansas City Chapter, an overview of Alphapointe resources and programs, and tours of Alphapointe’s on-site Clinical & Rehabilitation Center and manufacturing facility.
Join us on Sunday, October 23rd for a welcome reception. More details will be announced soon.
The 90-minute national webinar will feature guest presentations on emerging gene therapies from Opus, a potential anti-oxidative treatment from Nacuity, and a promising cell-based treatment from OkuloVision. The panel will answer questions from the audience on a wide range of research, clinical, and therapy development topics.